Theoharides T.C. Valent P. Akin C.

Mast Cells, Mastocytosis, and Related Disorders.

N Engl J Med. 2015; 373: 163-172https://doi.org/10.1056/NEJMra1409760Cohen S.S. Skovbo S. Vestergaard H. et al.

Epidemiology of systemic mastocytosis in Denmark.

Br J Haematol. 2014; 166: 521-528Pulfer S. Ziehfreund S. Gebhard J. et al.

Health-Related Quality of Life and Influencing Factors in Adults with Nonadvanced Mastocytosis—A Cross-Sectional Study and Qualitative Approach.

J Allergy Clin Immunol In Pract. 2021; 9: 3166-3175.e2Carter M.C. Metcalfe D.D. Komarow H.D.

Mastocytosis.

Immunol Allergy Clin. 2014; 34: 181-196

Systemic mastocytosis.

Annu Rev Med. 2004; 55: 419-432Valent P. Akin C. Hartmann K. et al.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.

Hemasphere. 2021; 5: e646Siebenhaar F. Akin C. Bindslev-Jensen C. et al.

Treatment strategies in mastocytosis.

Immunol Allergy Clin. 2014; 34: 433-447Nanagas V.C. Kovalszki A.

Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.

Clin Rev Allergy Immunol. 2019; 57: 194-212Georgin-Lavialle S. Lhermitte L. Dubreuil P. et al.

Mast cell leukemia.

Blood. 2013; 121: 1285-1295Weiler C.R. Butterfield J.

Mast cell sarcoma: clinical management.

Immunol Allergy Clin North Am. 2014; 34: 423-432

Mastocytosis in Pregnancy.

Mastocytosis. 2020; : 187-205Lei D. Akin C. Kovalszki A.

Management of Mastocytosis in Pregnancy: A Review.

J Allergy Clin Immunol Pract. 2017; 5: 1217-1223Matito A. Alvarez-Twose I. Morgado J.M. et al.

Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases.

Int Arch Allergy Immunol. 2011; 156: 104-111Norström A. Radulovic N.V. Bullarbo M. et al.

Mast cell involvement in human cervical ripening.

Eur J Obstet Gynecol Reprod Biol. 2019; 238: 157-163Elieh Ali Komi D. Shafaghat F. Haidl G.

Significance of mast cells in spermatogenesis, implantation, pregnancy, and abortion: cross talk and molecular mechanisms.

Am J Reprod Immunol. 2020; 83: e13228Derbala Y. Elazzamy H. Bilal M. et al.

Mast cell–induced immunopathology in recurrent pregnancy losses.

Am J Reprod Immunol. 2019; 82: e13128Ciach K. Niedoszytko M. Abacjew-Chmylko A. et al.

Pregnancy and Delivery in Patients with Mastocytosis Treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM).

PLoS One. 2016; 11: e0146924

Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.

Am J Hematol. 2019; 94: 363-377Simionescu A.A. Stanescu A.M.A. Popescu F.D.

State-of-the-Art on Biomarkers for Anaphylaxis in Obstetrics.

Life (Basel). 2021; 11https://doi.org/10.3390/life11090870Valent P. Akin C. Metcalfe D.D.

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Blood. 2017; 129: 1420-1427

Treatment of systemic mastocytosis: Novel and emerging therapies.

Ann Allergy Asthma Immunol. 2021; 127: 412-419

Avapritinib for Systemic Mastocytosis.

Expert Rev Hematol. 2021; 14: 687-696

FDA drug labeling for pregnancy and lactation drug safety monitoring systems.

Semin Perinatol. 2015; 39: 520-523

The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.

J Midwifery Womens Health. 2017; 62: 308-316Butterfield J. Weiler C.R.

The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome.

J Allergy Clin Immunol In Pract. 2020; 8: 2533-2541Gilboa S.M. Ailes E.C. Rai R.P. et al.

Antihistamines and birth defects: a systematic review of the literature.

Expert Opin Drug Saf. 2014; 13: 1667-1698

Cromolyn sodium.

StatPearls Publishing, Treasure Island (FL)2021Tolar J. Tope W.D. Neglia J.P.

Leukotriene-receptor inhibition for the treatment of systemic mastocytosis.

N Engl J Med. 2004; 350: 735-736Sarkar M. Koren G. Kalra S. et al.

Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes.

Eur J Clin Pharmacol. 2009; 65: 1259-1264Bonham C.A. Patterson K.C. Strek M.E.

Asthma Outcomes and Management During Pregnancy.

Chest. 2018; 153: 515-527Namazy J.A. Blais L. Andrews E.B. et al.

Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.

J Allergy Clin Immunol. 2020; 145: 528-536.e1

Maternal use of anti-asthmatic drugs and infant congenital malformations. maternal drug use and infant congenital malformations.

Springer International Publishing, 2019: 353-365Cardet J.C. Akin C. Lee M.J.

Mastocytosis: update on pharmacotherapy and future directions.

Expert Opin Pharmacother. 2013; 14: 2033-2045Hartmann K. Gotlib J. Akin C. et al.

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.

J Allergy Clin Immunol. 2020; 146: 356-366. e4

Finding the right KIT inhibitor for advanced systemic mastocytosis.

Nat Med. 2021; 27: 2081-2082Watson K.D. Arendt K.W. Watson W.J. et al.

Systemic mastocytosis complicating pregnancy.

Obstet Gynecol. 2012; 119: 486-489Kehoe S.L. Bathgate S.L. Macri C.J.

Use of a Doula for Labor Coaching in a Patient With Indolent Systemic Mastocytosis in Pregnancy.

Obstet Gynecol. 2006; 107: 514-516Madendag I.C. Madendag Y. Tarhan I. et al.

Mastocytosis in Pregnancy.

Taiwanese J Obstet Gynecol. 2010; 49: 192-196Hermans M.A.W. Arends N.J.T. Gerth van Wijk R. et al.

Management around invasive procedures in mastocytosis: An update.

Ann Allergy Asthma Immunol. 2017; 119: 304-309Worobec A.S. Akin C. Scott L.M. et al.

Mastocytosis complicating pregnancy.

Obstet Gynecol. 2000; 95: 391-395